Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2026-03-26 @ 3:14 PM
Ignite Modification Date:
2026-03-26 @ 3:14 PM
NCT ID:
NCT07432295
Eligibility Criteria:
Inclusion Criteria:
* Histologically confirmed unresectable, locally advanced, or metastatic gastric, gastroesophageal junction (GEJ), or esophageal adenocarcinoma (EAC).
* Treatment-naïve for advanced/metastatic disease (prior adjuvant/neoadjuvant therapy allowed if ≥6 months since last dose).
* CLDN18.2 positive (membrane intensity score ≥1+ on ≥1% of tumor cells).
* PD-L1 positive (CPS ≥1).
* At least 1 measurable lesion per RECIST v1.1.
* ECOG performance status 0 or 1.
* Adequate organ function, including:
* Hematologic: WBC ≥2,000/μL; ANC ≥1,500/μL; platelets ≥100,000/μL; hemoglobin ≥9 g/dL
* Hepatic: AST/ALT ≤3×ULN (≤5×ULN if liver metastases); bilirubin ≤1.5×ULN (≤3×ULN if Gilbert's)
* Renal: Creatinine ≤1.5×ULN or eGFR ≥50 mL/min/1.73 m²
* Life expectancy ≥90 days.
* Women of childbearing potential (WOCBP) and men must use effective contraception during the study and for a defined period after treatment.
* Willing and able to provide informed consent and comply with study procedures
Exclusion Criteria:
* HER2-positive tumors.
* Second malignancy within 3 years, except certain skin or cervical cancers.
* Active or unstable gastrointestinal ulcer or bleeding within 6 weeks.
* Active autoimmune disease requiring systemic therapy within past 2 years or ongoing immunosuppressive therapy.
* Active pneumonitis or history requiring steroids/immunosuppressive therapy within 3 years.
* Participation in another therapeutic clinical trial.
* Major surgery or significant injury within 4 weeks prior to first dose, or planned major surgery within 6 months.
* Radiotherapy within protocol-specified timeframes without adequate recovery.
* Active CNS metastases or carcinomatous meningitis (previously treated brain metastases allowed if stable).
* Significant cardiovascular disease (NYHA Class 3-4 CHF, recent MI, unstable angina, TIA/stroke, or major cardiac procedures within 6 months).
* Active or uncontrolled HIV, hepatitis B, or hepatitis C infection, or immunodeficiency (controlled infection allowed).
* Receipt of live vaccine within 30 days or other vaccines within 7 days of first dose.
* Active infection requiring parenteral therapy.
* Known hypersensitivity to study drug components (e.g., DPD deficiency).
* Any other condition or laboratory abnormality that, in the investigator's judgment, increases risk or interferes with study participation.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT07432295
Study Brief:
Protocol Section:
NCT07432295